RAT-HEMATO : Return to Work After Malignant Hemopathy

Recruiting now · Not applicable

Conditions studied: Leukemia, Lymphoma, Multiple Myeloma

In brief

Return to work (RTW) of patients after cancer treatment has been a topic of growing interest for the past two decades. Advances in cancer care have led to better patient survival, with some cancers considered as chronic or even cured diseases. The return of patients to their "pre-cancer life" can thus become an objective. Indeed, RTW after cancer is associated with improved quality of life for patients in several studies (improved financial status, improved social contacts, return of functional abilities and improved self-esteem). However, many difficulties can interfere with RTW. Many factors have been identified: disease, treatment, patient and occupational factors. The feeling of "return-to-work self-efficacy" is one of the main psychological determinants and its interest has been recently demonstrated in oncology. It corresponds to a cognitive mechanism based on expectations and/or beliefs of an individual about being able to carry out the actions required to achieve a goal, in this case RTW. The majority of studies on RTW concerns solid cancer and are retrospective. Very few studies have focused on hematological malignancies, whose prognosis was, until recently, worse. Moreover, very few interventional studies exist. There is therefore a significant need for prospective studies with appropriate methodological tools to reliably assess the benefit of interventional measures on RTW. The investigators propose to conduct a prospective, comparative, randomized, multicenter study evaluating the impact of an early RTW-consultation in patients who have been treated for a hematological malignancy. The investigators hypothesize that this consultation will improve patients' RTW rates and RTW quality.

Key facts

Study ID

NCT06262789

Run by

University Hospital, Angers

People needed

264

Starts

2024-09-27

Expected to finish

2027-09-01

Last updated by the study team

2026-08-10

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient with hematological malignancy controlled after treatment
• Induction/consolidation chemotherapy completed (excluding maintenance therapy)
• Patient aged 18 to 55
• Patient having worked at least 6 months in the 2 years before diagnosis of hematological malignancy
• Patient who has not yet returned to work since diagnosis of hematological malignancy
• Signed informed consent form

You may not qualify if…

• Patient choosing not to return to work
• Patient not affiliated to a social security system
• Patient with legal guardian or legal trustee
• Patient not understanding French
• Patient with severe cognitive impairment at diagnosis, incompatible with the study

Where it is running

• Angers University hospital — Angers, France (enrolling)
• Brest University Hospital, Morvan Site — Brest, France (enrolling)
• Centre Henri Becquerel — Rouen, France (enrolling)
• Tours University Hospital, Bretonneau Site — Tours, France (enrolling)
• Pays de Morlaix Hospital — Morlaix, France
• Rennes University Hospital, Pontchaillou site — Rennes, France
• Rouen University Hospital — Rouen, France
• Caen University hospital — Caen, France
• Le Havre Hospital Group — Montivilliers, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.